Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-15 for sleep disorders in children with neurodevelopmental disorders
NCT02757079Phase 3Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Jun 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of melatonin in sleep disorder, sponsored by Nobelpharma Co., Ltd. Primary endpoint: Sleep latency with electronic sleep diary at 10 weeks. Started Jun 2016; status: completed.
02
Drugs
melatonin
03
Conditions
sleep disorder
Beyond the preview
Go deeper on NCT02757079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02757079.